PMID: 3746546Sep 1, 1986Paper

Staphylococcus epidermidis-associated enterocolitis

The Journal of Pediatrics
J A GruskayJ Gerdes

Abstract

Nineteen infants (mean +/- SD gestational age 30 +/- 2 weeks, birth weight 1.28 +/- 0.53 kg) with Staphylococcus epidermidis bacteremia were found on retrospective chart review to have had signs and symptoms of acute enterocolitis. This S. epidermidis-associated enterocolitis constituted 37% of the 51 cases of enterocolitis and 23% of the 81 cases of S. epidermidis sepsis during the study period. S. epidermidis-associated enterocolitis was relatively mild compared with other forms of enterocolitis. Although abdominal radiographs showed markedly abnormal bowel gas patterns with distended bowel loops and bowel wall edema, only one infant had pneumatosis intestinalis and none had portal venous or free intraperitoneal gas. Only three infants had neutropenia, and five had thrombocytopenia. None of these infants required surgical intervention. Although bloody stools often persisted for weeks, none of the neonates had prolonged feeding intolerance or development of a stricture. We conclude that S. epidermidis infection is commonly associated with a mild form of enterocolitis in the neonate and that this association should be considered when selecting antibiotics for therapy.

References

Apr 1, 1978·The Journal of Pediatrics·M J BellT Brotherton
Feb 1, 1976·Pediatrics·L S BookA L Jung
May 1, 1983·American Journal of Diseases of Children·S BaumgartR A Polin
May 1, 1983·American Journal of Diseases of Children·J C Le GuennecB Billon
Jul 1, 1982·American Journal of Diseases of Children·R M Kliegman, A A Fanaroff
Oct 1, 1980·The Journal of Infectious Diseases·P A JordanH Baer
Oct 1, 1981·Archives of Disease in Childhood·O BattistiP A Davies

❮ Previous
Next ❯

Citations

May 7, 2008·Pediatric Surgery International·Miguel Sáenz de Pipaón MarcosJosé Quero Jiménez
Jul 1, 1990·The Journal of Pediatrics·D W Scheifele
Oct 1, 1990·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·P Weidenfeller, W Fegeler
Mar 17, 1999·The Journal of Experimental Medicine·C MehlinS J Klebanoff
Apr 3, 2014·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Nizami DuranKemal Jenedi
Jul 18, 2009·Digestive Diseases and Sciences·Zheng LinEmilia Mia Sordillo
Apr 1, 1987·Current Problems in Pediatrics·R M Kliegman, M C Walsh
Aug 1, 1992·The Journal of Hospital Infection·A SaveyB L Salle
Aug 1, 1993·Journal of Pediatric Surgery·A PierroD A Lloyd
Jan 1, 1988·Journal of Pediatric Surgery·D L MollittJ L Talbert
Oct 1, 1995·The Journal of Hospital Infection·P C NgK Liu
Feb 1, 1988·Journal of Clinical Microbiology·D W Scheifele, G L Bjornson

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.